6-fluoro-2-(pyrrolidin-1-yl)-3,4-dihydronaphthalene | 113075-42-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 6-fluoro-2-(pyrrolidin-1-yl)-3,4-dihydronaphthalene
• 英文别名: 1-(6-fluoro-3,4-dihydro-2-naphthyl)pyrrolidine；6-fluoro-2-pyrrolidinyl-3,4-dihydronaphthalene；6-fluoro-2-pyrrolidinyl 3,4-dihydronaphthalene；1-(6-fluoro-3,4-dihydronaphthalen-2-yl)pyrrolidine
• CAS: 113075-42-6
• 化学式: C₁₄H₁₆FN
• 分子量: 217.286
• InChiKey: QHSGPWZTLYKJIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-fluoro-2-(pyrrolidin-1-yl)-3,4-dihydronaphthalene 在 水 、 溶剂黄146 作用下， 以 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 生成 (6-Fluoro-2-oxo-1,2,3,4-tetrahydro-naphthalen-1-yl)-acetonitrile
  参考文献：
  名称：

  N -(Sulfonamido)alkyl[tetrahydro-1 H -benzo[ e ]indol-2-yl]amines: potent antagonists of human neuropeptide Y Y5 receptor

  摘要：

  [3a,4,5,9b-Tetrahydro-1H-benzo[e]indol-2-yl]amines were prepared via reductive amination and concomitant cyclization of alpha-cyanomethyl-beta-aminotetralins. N-acylation with Omega-sulfonamido-carboxylic acids and subsequent reduction afforded a series of N-(sulfonamido)alkyl[tetrahydro-1H-benzo[e]indol-2-yl]amines, which bound to the human neuropeptide Y Y5 receptor with nanomolar affinity. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00676-9
• 作为产物：
  描述：

  对氟苯乙酰氯 在 三氯化铝 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 6-fluoro-2-(pyrrolidin-1-yl)-3,4-dihydronaphthalene
  参考文献：
  名称：

  The Synthesis of Novelcis-α-Substituted-β-aminotetralins

  摘要：

  Teteralones were converted, in 1 to 3 steps, to alpha-substituted tetralones. Subsequent reductive amination with ammonium acetate/sodium cyanoborohydride gave the corresponding alpha-substituted-beta-aminotetralins, on a multigram scale, with minimal chromatography for the entire transformation.

  DOI：

  10.1081/scc-120021500
• 作为试剂：
  描述：

  6-氟-3,4-二氢-1H-2-萘酮 、 四氢吡咯 、 对甲苯磺酸 在 6-fluoro-2-(pyrrolidin-1-yl)-3,4-dihydronaphthalene 、 丙烯酰胺 、 对甲苯磺酸 、 氮气 、 氯仿 、 水 、 silica gel 、 乙酸乙酯 作用下， 以 苯 为溶剂， 反应 6.5h， 以there was obtained 8-fluoro-1,4,5,6-tetrahydrobenzo[h]quinolin-3(2H)-one of melting point 223°-224°的产率得到8-fluoro-1,4,5,6-tetrahydrobenzo[h]quinolin-3(2H)-one
  参考文献：
  名称：

  Benzazecine derivatives for cognitive and memory functions

  摘要：

  式为##STR1##的苯并氮烷二酮，其中R.sup.1和R.sup.2独立地为氢或氯，R.sup.3为氢、氟、氯、溴或甲氧基，R.sup.4为氢、氯或甲氧基，而R.sup.5为氢、乙酰基、丙酰基、苯甲酰基、氯苯甲酰基、甲氧基苯甲酰基或苯乙酰基，但要求R.sup.1到R.sup.4中的2或3个基团为氢，以及许多相应的苯并[f]喹啉，可以通过氧化制备这些苯并氮烷二酮，适用于控制或预防哺乳动物的脑血管不足或改善认知功能。它们可以根据各种工艺生产，并可以制备成药物组合物。

  公开号：

  US04876340A1

文献信息

• N-substituted aminotetralins as ligands for the neuropeptide Y Y5
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：US06140354A1

  公开（公告）日：2000-10-31

  .beta.-Aminotetralin derivatives of the formula: ##STR1## which are ligands for the neuropeptide Y Y5 (NPY5) receptor, methods of preparation and pharmaceutical compositions containing a .beta.-aminotetralin derivative as the active ingredient are described. The .beta.-aminotetralins are useful in the treatment of disorders and diseases associated with NPY receptor subtype Y5.

  该公式的.beta.-氨基四氢萘衍生物：##STR1##，它们是神经肽Y Y5（NPY5）受体的配体，描述了制备方法和含有.beta.-氨基四氢萘衍生物作为活性成分的药物组合物。这些.beta.-氨基四氢萘在治疗与NPY受体亚型Y5相关的疾病和疾病中很有用。
• Process for the preparation of benzo (F) quinolinones
  申请人：Eli Lilly and Company

  公开号：US05239075A1

  公开（公告）日：1993-08-24

  This invention relates to a process for the preparation of hexa- and octahydrobenzo[f]quinolin-3-ones.

  这项发明涉及一种制备六氢和八氢苯并[f]喹啉-3-酮的过程。
• [EN] N-SUBSTITUTED AMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS<br/>[FR] AMINOTETRALINES N SUBSTITUEES, LIGANDS DU RECEPTEUR Y Y5 DU NEUROPEPTIDE SERVANT AU TRAITEMENT DE L'OBESITE ET D'AUTRES TROUBLES
  申请人：ORTHO-MCNEIL PHARMACEUTICAL, INC.

  公开号：WO1999055667A1

  公开（公告）日：1999-11-04

  (EN) $g(b)-Aminotetralin derivatives of formula (1): which are ligands for the neuropeptide Y Y5 (NPY5) receptor, methods of preparation and pharmaceutical compositions containing a $g(b)-aminotetralins derivative as the active ingredient are described. The $g(b)-aminotetralins are useful in the treatment of disorders and diseases associated with NPY receptor subtype Y5.(FR) L'invention porte sur des dérivés d'aminotétraline de formule (1) ligands du récepteur Y Y5 (NPY5) du neuropeptide, sur leurs procédés de préparation, et sur des compositions pharmaceutiques les contenant comme principe actif. Les aminotétralines servent pour le traitement de troubles et de maladies liées au sous-type Y5 du récepteur NPY.

  (中文) 描述了公式（1）的$g(b)-氨基四环素衍生物，它们是神经肽Y Y5（NPY5）受体的配体，以及制备方法和含有$g(b)-氨基四环素衍生物作为活性成分的制药组合物。$g(b)-氨基四环素衍生物对于治疗与NPY受体亚型Y5相关的疾病和疾病非常有用。
• Hydrocinnamic acid derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US05017608A1

  公开（公告）日：1991-05-21

  Hydrocinnamic acid derivatives of the formula ##STR1## wherein one or two of the symbols R.sup.1 to R.sup.4 are halogen or methoxy and the others are hydrogen; R.sup.5 is hydrogen or phenyl; R.sup.6 is a residue of the formula ##STR2## R.sup.7 is (C.sub.1 -C.sub.4)-alkyl, (C.sub.2 -C.sub.5)-alkanoylamino-(C.sub.2 -C.sub.5)-alkyl, amino or (C.sub.1 -C.sub.4)-alkoxyphenyl; R.sup.8 and R.sup.9 each, independently, are hydrogen or (C.sub.1 -C.sub.4)-alkyl; R.sup.10 is hydrogen and R.sup.11 is hydroxy or R.sup.10 and R.sup.11 taken together are oxo; R.sup.12 is hydrogen, (C.sub.1 -C.sub.10)-alkyl, pyridylmethyl or carbamoylmethyl; R.sup.13 is hydrogen, (C.sub.1 -C.sub.4)-alkyl and R.sup.14 is hydrogen, (C.sub.1 -C.sub.4)-alkyl, pyridyl, phenyl-(C.sub.1 -C.sub.4)-alkyl, carboxy-(C.sub.1 -C.sub.4)-alkyl, carbamoyl-(C.sub.1 -C.sub.4)-alkyl, (C.sub.1 -C.sub.4)-alkoxycarbonyl-(C.sub.1 -C.sub.4)-alkyl, di-(C.sub.1 -C.sub.4)-alkoxycarbonyl-(C.sub.2 -C.sub.5)-alkyl, piperidino-(C.sub.2 -C.sub.4)-alkyl or halopyridinecarboxamido-(C.sub.2 -C.sub.4)-alkyl or R.sup.13 and R.sup.14 taken together with the nitrogen atom are 4-(C.sub.1 -C.sub.4)-alkyl-piperazin-1-yl, as well as pharmaceutically accpetable salts or basic compounds of formula I with acids or of acidic compounds of formula I with bases are described. The compounds of formula I and their pharmaceutically acceptable salts are suitable for the control or prevention of cerebral insufficiency or for the improvement of cognitive functions.

  化合物式为##STR1##的羟基肉桂酸衍生物，其中R.sup.1至R.sup.4中的一或两个符号为卤素或甲氧基，其余为氢；R.sup.5为氢或苯基；R.sup.6为式子##STR2##的残基；R.sup.7为(C.sub.1-C.sub.4)-烷基，(C.sub.2-C.sub.5)-酰胺基-(C.sub.2-C.sub.5)-烷基，氨基或(C.sub.1-C.sub.4)-烷氧基苯基；R.sup.8和R.sup.9各自独立地为氢或(C.sub.1-C.sub.4)-烷基；R.sup.10为氢，R.sup.11为羟基或R.sup.10和R.sup.11一起为氧代基；R.sup.12为氢，(C.sub.1-C.sub.10)-烷基，吡啶基甲基或氨甲酰基甲基；R.sup.13为氢，(C.sub.1-C.sub.4)-烷基，R.sup.14为氢，(C.sub.1-C.sub.4)-烷基，吡啶基，苯基-(C.sub.1-C.sub.4)-烷基，羧基-(C.sub.1-C.sub.4)-烷基，氨甲酰基-(C.sub.1-C.sub.4)-烷基，(C.sub.1-C.sub.4)-烷氧基羧酰基-(C.sub.1-C.sub.4)-烷基，二-(C.sub.1-C.sub.4)-烷氧基羧酰基-(C.sub.2-C.sub.5)-烷基，哌啶基-(C.sub.2-C.sub.4)-烷基或卤代吡啶羧酰胺基-(C.sub.2-C.sub.4)-烷基，或R.sup.13和R.sup.14与氮原子一起为4-(C.sub.1-C.sub.4)-烷基哌嗪-1-基，以及式I的药学上可接受的酸盐或碱性化合物，或式I的酸性化合物与碱的药学上可接受的盐。式I的化合物及其药学上可接受的盐适用于控制或预防脑血管不足或改善认知功能。
• Benzo \x9bF! quinolinones
  申请人：Eli Lilly and Company

  公开号：US05670512A1

  公开（公告）日：1997-09-23

  This invention relates to hexa- and octaahydrobenzo\x9bf!quinolin-3-ones, pharmaceutical formulations containing those compounds and methods of their use as steroid 5.alpha.-reductase inhibitors.

  本发明涉及六和八氢化苯并[b]喹啉-3-酮，含有这些化合物的制药配方以及它们作为类固醇5α-还原酶抑制剂的使用方法。